Phase 1 of the clinical trial FHD-909 (LY4050784) is progressing according to schedule, with a primary focus on SMARCA4 (BRG1)-mutant cancers, particularly non-small cell lung cancer (NSCLC). The trial involves gradually increasing the dosage to determine the optimal level. This study aims to evaluate the efficacy and safety of the treatment in patients with these specific mutations. The trial is significant for potentially offering a new therapeutic option for patients with SMARCA4 mutations, particularly those with NSCLC.